DOCSLIB.ORG

1 Jasvinder Chawla, MD, MBA Chief Neurology, Hines Veterans Affairs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Jasvinder Chawla, MD, MBA Chief Neurology, Hines Veterans Affairs Jasvinder Chawla, MD, MBA Chief Neurology, Hines Veterans Affairs Hospital, Professor of Neurology, Loyola University Medical Medical Center Jasvinder Chawla, MD, MBA is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Clinical Neurophysiology Society, American Medical Association. Specialty Editor Board Francisco Talavera, PharmD, PhD Adjuct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Editor-in-Chief, Medscape Drug Reference Howard S Kirshner, MD Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine, Director, Vanderbilt Stroke Center, Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital, Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center. Chief Editor Helmi L Letsep, MD Professor and Vice Chair, Department of Neurology, Oregon Health and Science University School of Medicine, Associate Director, OHSU Stoke Center Additional Contributors Pitchaiah Mandava, MD, PhD Assistant Professor, Department of Neurology, Baylor College of Medicine, Consulting Staff, Department of Neurology, Michael E DeBakey Veterans Affairs Medical Center. Richard M Zweifler, MD Chief of Neurosciences, Sentara Healthcare, Professor and Chair of Neurology, Eastern Virginia Medical School. 1 Thomas A Kent, MD Professor and Director of Stroke Research and Education, Department of Neurology, Baylor College of Medicine, Chief of Neurology, Michael E DeBakey Veterans Affairs Medical Center. Course Content Definitions Practice Essentials Signs and symptoms of Hyperglycemia Hyperglycemia in Stroke Diabetes Mellitus Proposed mechanisms for Hyperglycemia and worsened outcomes Possible protective effects of Hyperglycemia in lacunar stroke subtype Hypoglycemia in stroke like occurrences Signs and symptoms of Hypoglycemia Evaluation of Glycemic level and stroke Hypoglycemic symptoms and manifestations Central nervous system Laboratory studies Imaging studies Management Hyperglycemia Hypoglycemia Diagnosis Routine tests CT scanning of head Therapy in Hyperglycemia Consultations Acute Hyperglycemic therapy Intensive insulin therapy Sulfonylurea agents Complications Therapy in Hypoglycemia 2 Definitions Hyperglycemia (also spelled hyperglycaemia or hyperglycæmia), is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/l (200 mg/dl), but symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/l (~250–300 mg/dl). A subject with a consistent range between ~5.6 and ~7 mmol/l (100–126 mg/dl) (American Diabetes Association guidelines) is considered slightly hyperglycemic, and above 7 mmol/l (126 mg/dl) is generally held to have diabetes. For diabetics, glucose levels that are too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dl) can produce noticeable organ damage over time. White hexagons in the image represent glucose molecules, which are increased in the lower image. Hypoglycemia, also known as low blood sugar, is a fall in blood sugar to levels below normal. This may result in a variety of symptoms including clumsiness, trouble talking, confusion, loss of consciousness, seizures or death. A feeling of hunger, sweating, shakiness and weakness may also be present. Symptoms typically come on quickly. The most common cause of hypoglycemia is medications used to treat diabetes mellitus such as insulin and sulfonylureas. Risk is greater in diabetics who have eaten less than usual, exercised more than usual or drunk alcohol. Other causes of hypoglycemia include kidney failure, certain tumours (such as insulinoma), liver disease, hypothyroidism, starvation, inborn error of metabolism, severe infections, reactive hypoglycemia and a number of drugs including alcohol. Low blood sugar may occur in otherwise healthy babies who have not eaten for a few hours. 3 The glucose level that defines hypoglycemia is variable. In people with diabetes, levels below 3.9 mmol/L (70 mg/dL) are diagnostic. In adults without diabetes, symptoms related to low blood sugar, low blood sugar at the time of symptoms and improvement when blood sugar is restored to normal confirm the diagnosis. Otherwise, a level below 2.8 mmol/L (50 mg/dL) after not eating or following exercise may be used. In new-borns, a level below 2.2 mmol/L (40 mg/dL), or less than 3.3 mmol/L (60 mg/dL) if symptoms are present, indicates hypoglycemia. Other tests that may be useful in determining the cause include insulin and C peptide levels in the blood. Practice Essentials Pre-existing hyperglycemia worsens the clinical outcome of acute stroke. Nondiabetic ischemic stroke patients with hyperglycemia have a 3-fold higher 30-day mortality rate than do patients without hyperglycemia. In diabetic patients with ischemic stroke, the 30-day mortality rate is 2-fold higher. With regard to hypoglycemia, the condition can mimic acute stroke or symptoms of transient ischemic attack (TIA). Signs and symptoms in Hyperglycemia The degree of hyperglycemia can change over time depending on the metabolic cause, for example, impaired glucose tolerance or fasting glucose, and it can depend on treatment. Temporary hyperglycemia is often benign and asymptomatic. Blood glucose levels can rise well above normal and cause pathological and functional changes for significant periods without producing any permanent effects or symptoms. During this asymptomatic period, an abnormality in carbohydrate metabolism can occur which can be tested by measuring plasma glucose. Chronic hyperglycemia at above normal levels can produce a very wide variety of serious complications over a period of years, including kidney damage, neurological damage, cardiovascular damage, damage to the retina or damage to feet and legs. Diabetic neuropathy may be a result of long-term hyperglycemia. Impairment of growth and susceptibility to certain infection can occur as a result of chronic hyperglycemia. Acute hyperglycemia involving glucose levels that are extremely high is a medical emergency and can rapidly produce serious complications (such as fluid loss through osmotic diuresis). It is most often seen in persons who have uncontrolled insulin-dependent diabetes. The following symptoms may be associated with acute or chronic hyperglycemia, with the first three composing the classic hyperglycemic triad: • Polyphagia – frequent hunger, especially pronounced hunger • Polydipsia – frequent thirst, especially excessive thirst • Polyuria – increased volume of urination (not an increased frequency, although it is a common consequence) • Blurred vision • Fatigue • Restlessness • Weight loss • Poor wound healing (cuts, scrapes, etc.) • Dry mouth • Dry or itchy skin • Tingling in feet or heels • Erectile dysfunction • Recurrent infections, external ear infections (swimmer's ear) • Cardiac arrhythmia 4 • Stupor • Coma • Seizures Frequent hunger without other symptoms can also indicate that blood sugar levels are too low. This may occur when people who have diabetes take too much oral hypoglycemic medication or insulin for the amount of food they eat. The resulting drop in blood sugar level to below the normal range prompts a hunger response. Polydipsia and polyuria occur when blood glucose levels rise high enough to result in excretion of excess glucose via the kidneys, which leads to the presence of glucose in the urine. This produces an osmotic diuresis. Signs and symptoms of diabetic ketoacidosis may include: • Ketoacidosis • Kussmaul hyperventilation (deep, rapid breathing) • Confusion or a decreased level of consciousness • Dehydration due to glycosuria and osmotic diuresis • Increased thirst • 'Fruity' smelling breath odour • Nausea and vomiting • Impairment of cognitive function, along with increased sadness and anxiety • Weight loss Hyperglycemia causes a decrease in cognitive performance, specifically in processing speed, executive function, and performance. Decreased cognitive performance may cause forgetfulness and concentration loss. Hyperglycemia in stroke Pre-existing hyperglycemia is found commonly in patients presenting with acute stroke and is reported to be present in 20 to 50% of patients. In many trials of thrombolytic agents, hyperglycemia occurred in about 20-30% of subjects. Although confounded by other factors, such as severity of the infarct, hyperglycemia in the face of acute stroke worsens clinical outcome. Nondiabetic hyperglycemic ischemic stroke patients have a 3- fold higher 30-day mortality and diabetic patients have a 2-fold 30-day mortality. In several trials involving thrombolytic and anticoagulation therapy in patients with stroke, hyperglycemia appears to be an independent risk factor for worsened outcome. In addition, hyperglycemia has been suggested as an independent risk factor in hemorrhagic conversion of the stroke after administration of thrombolytic therapy. Several case reports describe hypoglycemia mimicking acute stroke or symptoms of transient ischemic attack (TIA). Berkovic et al reported that hypoglycemia was the cause of symptoms mimicking acute stroke in 3 of 1460 patients admitted to their stroke unit over a 5-year period. Diabetes mellitus Diabetes mellitus is an independent
Load more

Recommended publications
  • Reactive Hypoglycemia from Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
    Open Access Case Report DOI: 10.7759/cureus.16112 Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves Ayesha Akram 1, 2 1. Internal Medicine, Combined Military Hospital, Rawalpindi, PAK 2. Internal Medicine, Rawalpindi Medical University, Rawalpindi, PAK Corresponding author: Ayesha Akram, [email protected] Abstract Metformin rarely, if ever, causes hypoglycemia when it is used as labeled. A 55-year-old woman presented to the medicine ward with an altered level of consciousness. She had been reviewed in an outpatient department three days earlier and prescribed 500 mg two times per day of metformin immediate-release (Met IR) for newly diagnosed type 2 diabetes mellitus (T2DM), to which she had been adherent; however, she had been experiencing intermittent episodes of hypoglycemia after taking the medication prescribed to treat her T2DM. On physical examination, she was diaphoretic and disoriented but responsive to sensory stimuli. In the ward, she received 25 ml of intravenous dextrose as the initial blood glucose reading was low at 54 mg/dl, and 4 ounces of apple juice additionally two hours later as her blood glucose level fell below 70 mg/dl again. She was no longer hypoglycemic a few hours later, and there was a significant neurological improvement. The remainder of the laboratory results, including serum renal and liver function tests, were normal. Met IR was discontinued, and metformin extended-release (Met XR) 500 mg/day was initiated at discharge. The patient's hypoglycemic episodes resolved within days after the initiation of Met XR.
    [Show full text]
  • Glucose Regulation in Diabetes
    Glucose Regulation in Diabetes Samantha Lozada Advised by Charles S. Peskin and Thomas Fai Glucose 1 Abstract Complicated and extensive models of glucose regulation, involving several variables, have been developed over the years. Our research specifically focuses on the feedback loop between insulin and glucagon. Although our model is simpler than a model including state variables such as non-esterified fatty acids concentration in the blood plasma, β-cell mass, TAG content of lipocytes, and/or leptin concentrations in the blood plasma, we are still able to simulate most of the key effects of diabetes and other health problems on glucose regulation; such as, hyperglycemia, hyperinsulinism, and insulin shock (hypoglycemia). We are even able to simulate eating a bowl of vanilla ice cream! 2 Introduction For most of our qualitative and quantitative experimentations we worked with MATLAB, a computer programming language and data visualization software, which offers a rich set of tools for solving problems in engineering, scientific, computing, and mathematical disciplines, such as a graphical user interface. Our model is a refinement of a realistic model developed by Cobelli et al. (1982). Despite the fact that the paper is nearly 28 years old, the experimental data of diagnostic tests used by medical professionals, such as the Intravenous Glucose Tolerance Test (IVGTT), correlates with our simulated graphs. From a Biological Perspective Regulation in a Healthy System In order for us to model any biological system, we need to first understand exactly what is happening within a human body. We need to ask what causes this effect and why. To answer these questions we need to identify the key organs and hormones, and then see how they interact within our bodies.
    [Show full text]
  • Religious Fasting, Ramadan and Hypoglycemia in People with Diabetes
    VOLUME 7 > ISSUE 01 > JUNE 30 2014 SPOTLIGHT ARTICLE Diabetic Hypoglycemia June 2014, Volume 7, Issue 1: page 15-19 Religious fasting, Ramadan and hypoglycemia in people with diabetes Alia Gilani1, Melanie Davies2, Kamlesh Khunti2 1 NHS Glasgow, United Kingdom 2 Leicester Diabetes Centre, Leicester General Hospital, Leicester, United Kingdom Abstract Most Muslims with diabetes will take part in Ramadan even though they may be exempt from doing so. In some countries a religious fast can last between 10 and 21 hours. The main risk of fasting to people with diabetes is hypoglycemia. People with diabetes who fast may have to alter the dose of their medications or modify their therapeutic regimen to avoid hypoglycemia, which can have adverse effects on glycemic control. Therapies which pose a high risk of hypoglycemia when used during fasting are sulfonylureas and insulin therapy. Metformin, incretin therapies and the newer sodium glucose co-transporter 2 inhibitor class have a low risk of hypoglycemia. The practice of fasting during Ramadan is advocated for all healthy individuals. If deemed detrimental to health then a person can be considered exempt from fasting; this includes frail and elderly people, pregnant and breast feeding women, children and people with multi-morbidities. Keywords: diabetes, hypoglycemia, Ramadan, religious fasting Introduction the Islamic calendar, the risks associated with prolonged fasting and how it should be managed. Living in a diverse society, it is important that healthcare professionals are kept informed about cultural and religious Fasting during Ramadan practices, which can affect the control of diabetes. The practice of fasting by Muslims has implications for Muslim What does fasting entail? people with diabetes, in particular an increased risk of Ramadan in Arabic is translated as “sawm”, literally hypoglycemia during the period of Ramadan and at other meaning “abstention from”.
    [Show full text]
  • Table of Contents
    DISCLAIMER The information contained within this document is restricted to and intended for professional use by licensed health care providers. The statements made should not be construed as a claim, nor does it represent any particular product procedure or advice as constituting a specific cure, whether palliative or ameliorative. Procedures and products mentioned are designed to support the client’s health and may be considered as support for other procedures deemed necessary by the practitioner. Although specific manufacturers make the supplements, herbs and homeopathies referenced in this document, the opinions expressed are those of the author and are not those of any of the manufacturers. This document is not designed to replace medical advice or medical treatments, but to be used adjunctively in the care and support of health and vitality. 9 © Copyright 2005 Return to Table of Contents . CHAPTER II: SUGAR HANDLING BLOOD SUGAR STABILIZATION RELATED CONDITIONS • Hypoglycemia PROTOCOL AT A GLANCE • Reactive Hypoglycemia • Low blood sugar Primary Supplemental Support • Syndrome X Bio-Glycozyme Forte • Triglycerides high Biomega-3 • Carbohydrate sensitivity Secondary Supplemental Support • Pre-diabetic Whey Protein Isolate • B vitamin deficiency Amino Acid Quick Sorb • Sugar sensitivity Beta-TCP • Food cravings ADHS Cytozyme-PAN • Carbohydrate cravings Cytozyme-LV Cytozyme-AD PHYSIOLOGIC CONSIDERATIONS Tri-Chol Blood sugar problems begin in childhood with excess use of sugary snacks and drinks. This is extremely common today. The U.S. Department of Agriculture estimates that the average American consumes from 150 to 180 pounds of sugar each year––an unbelievable amount compared to two or three hundred years ago when normal sugar consumption was one to five pounds per year.
    [Show full text]
  • Study Protocol
    CLINICAL TRIAL REPORT ZP4207-16136 (ZEA-DNK-01711) 16.1 TRIAL INFORMATION 16.1.1 PROTOCOL AND PROTOCOL AMENDMENTS This appendix includes Document Date, Version Clinical Trial Protocol 18 January 2017, Version 1 Amendment 01 08 May 2017 Clinical Trial Protocol 08 May 2017, Version 2 Amendment 02 21 August 2017 Clinical Trial Protocol 21 August 2017, Version 3 Section 16.1.1: Protocol and Protocol Amendments Clinical Trial Protocol, final version 1 ZP4207-16136 (ZEA-DNK-01711) Clinical Trial Protocol A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon Compared to GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1DM) Sponsor code: ZP4207-16136 SynteractHCR: ZEA-DNK-01711 EudraCT number: 2017-000062-30 Coordinating investigator: Linda Morrow, MD Prosciento 855 Third Avenue 91911 Chula Vista CA, USA Sponsor: Zealand Pharma A/S Smedeland 36 2600 Glostrup, Copenhagen Denmark Version: final version 1 Date: 18 January 2017 GCP statement This trial will be performed in compliance with Good Clinical Practice (GCP), the Declaration of Helsinki (with amendments) and local legal and regulatory requirements. 18 Jan 2017 CONFIDENTIAL Page 1/48 Clinical Trial Protocol, final version 1 ZP4207-16136 (ZEA-DNK-01711) Title: A phase 3, randomized, double-blind, parallel group safety trial to evaluate the immunogenicity of dasiglucagon compared to GlucaGen® administered subcutaneously in patients with type 1 diabetes mellitus (T1DM) I agree to conduct this trial according to the Trial Protocol. I agree that the trial will be carried out in accordance with Good Clinical Practice (GCP), with the Declaration of Helsinki (with amendments) and with the laws and regulations of the countries in which the trial takes place.
    [Show full text]
  • Neurologic Manifestations of Hypoglycemia
    13 Neurologic Manifestations of Hypoglycemia William P. Neil and Thomas M. Hemmen University of California, San Diego United States of America (USA) 1. Introduction Unlike most other body tissues, the brain requires a continuous supply of glucose. It has very limited endogenous glycogen stores, and does not produce glucose intrinsically.1 Although it accounts for 2% of body weight, the brain utilizes 25% of the body’s glucose due to its high metabolic rate.2, 3 Evidence for the brains sole reliance on glucose came from obtaining a respiratory quotient of one after measuring differences between arterial and venous content of oxygen and carbon dioxide in blood traveling through the brain.4 In the past, neurons were thought to directly metabolize glucose, however, more recent studies suggest astrocytes may play an important role in glucose metabolism.5 Astrocytic foot processes surround brain capillaries, which deliver glucose to the brain. With this, they form the first cellular barrier for entering glucose.5 Astrocytes contain the non-insulin dependent GLUT1 transporter, as well as the insulin dependent GLUT4 transporter, suggesting a possible role for astrocytes in regulating and storing brain glucose in an insulin dependent and independent manner (see figure 1).6-8 In addition to glucose, the brain contains a very limited store of glycogen, (between 0.5 and 1.5 g, or about 0.1% of total brain weight). Unlike peripheral tissue, where glycogen is readily mobilized during hypoglycemia, the brain can only function normally for a limited duration. Glycogen content seems to fall in areas of highest brain metabolic rate, suggesting at least some, albeit limited role as fuel during hypoglycemia.7 Although the brain relies primarily on glucose during normal conditions, it can use ketone bodies during starvation.
    [Show full text]
  • Blood Sugar the Hidden Factor in Health
    Blood Sugar The Hidden Factor in Health Disorders in blood sugar balance disrupt all aspects of human physiology. To understand this, we must keep in mind that our bodies primarily produce their energy from converting glucose (blood sugar) into ATP. If this system is not working properly, health cannot be achieved. Blood sugar disorders are extraordinarily common in the U.S. today. Much (but not all) of the prob- lem can be placed on the Standard American Diet that is high in saturated fats and sugars while being low in essential fatty acids and fiber. In the past decade, there has been an explosion in the number of cases of diabetes, which only figures to grow in the decades ahead. Insulin Insulin is a protein hormone secreted by the pancreas. Its primary job is to stimulate the uptake of glucose from our blood into our cells. Cell membranes have a lipid layer thru which glucose cannot pass on its own. It has to be carried across with the assistance of insulin. Once inside the cells, glu- cose can be used for energy. All foods are ultimately converted into glucose. An increase of glucose in the bloodstream stimulates the release of more insulin. Insulin promotes the production of glycogen, which is the form that glucose is stored in, for later use. Insulin also promotes the formation of lipids, triglyceride and protein. Alterations in insulin are responsible for causing metabolic disorders such as hypoglycemia and diabetes. Hypoglycemia If the pancreas overreacts to a sudden surge in glucose, it will release excess insulin which will subsequently cause a drop in blood sugar.
    [Show full text]
  • The Impact of Patient Information Leaflets to Prevent Hypoglycemia In
    The impact of patient information leaflets to prevent hypoglycemia in out-patients with type 2 diabetes mellitus El impacto de los folletos de información al paciente para prevenir la hipoglucemia en pacientes ambulatorios con diabetes mellitus tipo 2 Veintramuthu Sankar1, Abdul Sherif2, Anita Ann Sunny3, Grace Mary John2, Senthil Kumar Rajasekaran3 1 Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, India 2 Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, India 3 Department of Endocrinology, PSG Hospitals, PSG Institute of Medical Sciences and Research, Coimbatore, India http://dx.doi.org/10.30827/ars.v60i1.7614 Artículo original ABSTRACT Original Article Hypoglycemia is a significant complication of intensive diabetes therapy, a true medical emergency, which requires prompt recognition and treatment to prevent organ and brain damage. Therefore, knowl- Correspondencia Correspondence edge about diabetes can play an important role in maintaining glycemia control and prevent hypogly- Veintramuthu Sankar cemic complications. [email protected] Aim: The aim of the study is to develop and assess the impact of patient information leaflets to prevent hypoglycemia in outpatients with type 2 diabetes mellitus and to study the effect of prescribed drugs Financiación Fundings pattern in patients. Fund granted by College management Material & Methods: This open labelled, interventional study was conducted in the endocrinology Out and the research work was approved Patient Department (OPD) in a tertiary care hospital over a period of 9 months in 55 patients. The infor- for the award of Degree of Master of pharmacy by The Tamilnadu Dr.MGR mation was provided to patients through a developed patient information leaflet and their awareness Medical University, Chennai, India and glycemic status were assessed by an internally institution developed vernacular language based validated questionnaire.
    [Show full text]
  • Reduction in SGLT1 Mrna Expression in the Ventromedial
    Page 1 of 25 Diabetes Reduction in SGLT1 mRNA Expression in the Ventromedial Hypothalamus Improves the Counterregulatory Responses to Hypoglycemia in Recurrently Hypoglycemic and Diabetic Rats Xiaoning Fan1 Owen Chan1 Yuyan Ding1 Wanling Zhu1 Jason Mastaitis1 Robert Sherwin1 1Yale School of Medicine, Department of Internal Medicine - Section of Endocrinology1, New Haven, CT, 06520 U.S.A. Please address correspondences to Dr. Robert Sherwin, Yale University School of Medicine, Department of Internal Medicine – Section of Endocrinology, 300 Cedar Street, TAC S141D, New Haven, CT, U.S.A. Telephone: (203) 785-4183, E-mail: [email protected] Abstract Word Count: 200 Word Count: 3315 Figure Count: 6 Tables: 2 Keywords: SGLT-1, hypoglycemia, recurrent hypoglycemia, diabetes, glucose sensing 1 Diabetes Publish Ahead of Print, published online June 30, 2015 Diabetes Page 2 of 25 ABSTRACT：：： The objective of this study was to determine whether the sodium-glucose transporter SGLT1 in the ventromedial hypothalamus (VMH) plays a role in glucose sensing and in regulating the counterregulatory response to hypoglycemia. Furthermore, if it does, whether knockdown of SGLT1 in the VMH can improve counterregulatory responses to hypoglycemia in diabetic rats or those exposed to recurrent bouts of hypoglycemia (RH). Normal Sprague-Dawley (SD) rats, as well as RH or streptozotocin (STZ)-diabetic rats received bilateral VMH microinjections of an adeno-associated viral vector (AAV) containing either the SGLT1 shRNA or a scrambled RNA sequence. Subsequently, these rats underwent a hypoglycemic clamp to assess hormone responses. In a sub-group of rats, glucose kinetics was determined using tritiated glucose. The shRNA reduced VMH SGLT1 expression by 53% in non-diabetic rats.
    [Show full text]
  • Blood Glucose Screener Training and Procedure
    LIONS DIABETIC AWARENESS FOUNDATION OF MD-35 www.dafmd35.org FLORIDA LIONS DIABETIC RETINOPATHY FOUNDATION www.fldrf.org BBLLOOOODD GGLLUUCCOOSSEE SSCCRREEEENNEERR TTRRAAIINNIINNGG AANNDD PPRROOCCEEDDUURREE MMAANNUUAALL Contact Lion Norma Callahan, PDG. [email protected] For any changes, corrections, or questions. REV 10 (March 1, 2017) 1 TRAINING Introduction 3 On-Line Resources 4 Training Objectives 5 Lions and Diabetes Awareness Why? 8 Diabetes Awareness Grant - What Is It? 9 Sight First Grant 10 Overview of Diabetes 12 Classification of Diabetes 13 Awareness/Screening for Diabetes 17 Hyperglycemia/Hypoglycemia 18 Retina Screener Training 21 What do we tell clients? 24 Diagnosis 26 Treatment 27 Lifestyle Changes/Successful Management 29 Nutrition 30, 34 Glycemic Index 32 Glycemic Load 33 Complications Caused by Diabetes 37 Understanding Diabetic Retinopathy 38 Goals for Glycemic Control 40 Childhood Obesity/Diabetes in Children 41 PROCEDURE Arrangements 47 Equipment 48 Reporting Requirements 49 Setting - Up 50 Screening Procedure 52 Counseling 54 Ordering New Supplies 57 Closing 58 Recertification/Expectations 59 Screening in Schools 60 How to Do a Finger Stick on a Child 60 How to Discuss Results with Clients 61 What to Do In An Emergency 62 APPENDIX Anatomy of the Endocrine System 63 Glossary 65 Reference 77 2 INTRODUCTION This manual will aid Lions involved in Blood Glucose screening and education to better understand the complex condition known as Diabetes. Since some personnel will be more knowledgeable and experienced than others, there is an index listing various topics for easy reference, and a glossary defining complex terminology. This manual is intended to quickly familiarize users with the disease of Diabetes.
    [Show full text]
  • Jack L. Snitzer,D.O
    JACK L. SNITZER,D.O. Internal Medicine Board Review Course 2019 ENDOCRINE PANCREAS JACK L. SNITZER, D.O. Peninsula Regional Endocrinology 1415 S. Division Street Salisbury, MD 21804 Phone:410-572-8848 Fax:410-572-6890 E-Mail: [email protected] Endocrine Pancreas n Alpha Cells: Glucagon n Beta Cells: Insulin n Delta Cells: Somatostatin n D1 Cells: Vasoactive intestinal Polypeptide (VIP) n F Cells: Pancreatic Polypeptide (PP) n G Cells: Gastrin GLUCAGONOMA -Glucagonoma Causes increased glucose production. Rare, often malignant tumors. Classic Rash: Necrolytic Migratory Erythema Painful glossitis, angular stomatitis. Tx: Surgery, Octreotide INSULINOMA -Insulinoma Spontaneous hypoglycemia. 80% are benign. Usually very small tumors. Second most common pancreatic tumor found in MEN 1. INSULINOMA -Insulinoma Dx: elevated insulin and C-peptide level with simultaneously low glucose and symptoms. -Fasting glucose <50 mg/dl. Tx: Surgery. Octreotide to palliate. Hypoglycemia: other causes in non- diabetics • Reactive hypoglycemia (generally in obese patient with metabolic syndrome) • Malnutrition (celiac disease, eating disorder, etc.) • Cortisol insufficiency (adrenal or pituitary cause) • Nesidioblastosis (for instance: post-gastric bypass: islet cell hyperplasia) Hypoglycemia: other causes in non- diabetics • Liver disease • Surreptitious, malicious or inadvertent use of insulin. In this case, when the BG is low, insulin level will be high and C-peptide level will be low. Need to obtain these levels before treating with glucose or glucagon. • Surreptitious use of insulin secretagogue. Insulin and c- peptide levels will be high when BG is low. • Glucometer error (glucose meters are inaccurate when the BG is low); or hypoperfusion of the fingers Hypoglycemia: other causes in non- diabetics • Remember: early hypoglycemia symptoms (shakes, sweats, anxiety, hunger) are due to catecholamine release.
    [Show full text]
  • Dr. Ritamarie Loscalzo 10Min. Transcript
    The Blood Sugar Spectrum & Women’s Health. Clinical training by Dr. Ritamarie Loscalzo and Dr. Jessica Drummond Jessica Drummond: Hi, everyone. It's Jessica Drummond here from the Integrative Women's Health Institute and I am honored to be joined by Dr. Ritamarie Loscalzo. She is essentially an expert in a part of nutrition that she has termed, and I think it's a perfectly a perfect term for this, nutritional endocrinology. She really thinks about hormones from a very root cause perspective for men and women. Today, we're going to be talking about how insulin resistance, blood sugar imbalances impact hormonal health for women and in general. So welcome, Ritamarie. How are you? Dr. Ritamarie L: I'm really good. Thank you, Jessica. I'm excited to be talking to you today and to share this passion of mine. Jessica Drummond: Excellent. So I'll let you dive right in. Ritamarie's got a presentation for us and I may bust in from time to time and ask some questions. Dr. Ritamarie L: Please do. Let's make it fun. All right. So, welcome, everybody, and thank you for your attention. I'm excited to be here and talk to Jessica's group. I know that you guys are really into female health and women's health, and a big part of that obviously is hormones. Dr. Ritamarie L: The first thing that I like to say when I talk about hormones is that hormones is not just about sex. I know we all want to go to the bedroom, we all want to talk about the sex hormones, but there's so many other hormones that play into how those sex hormones function.
    [Show full text]